Clinical trials: Nutritional Risk
Diabetes, Hypertension
Multi-Targeted Cardiac Risk Intervention in Type 2 Diabetes
Our study intends to test the efficacy of pharmacist-led group interventions on a weekly basis for 4-weeks, then on a monthly basis for 5 additional months to achieve concomitant reductions in hemoglobin A1c, lipids and blood…
- Conditions
- Diabetes, Hypertension, Dyslipidemia
- Trial name
- NCT00409240
- Testing
- MEDIC
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- Providence VA Medical Center
Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Diabetes
Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"
The study will determine whether the anti-CD3 monoclonal antibody, teplizumab, can help to prevent or delay the onset of type 1 diabetes (T1D) in relatives determined to be at very high risk for developing the disease.
- Conditions
- Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Diabetes, High Risk, Impaired Glucose Tolerance
- Trial name
- NCT01030861
- Testing
- Teplizumab
- Where
- 19 sites in United States, Canada and 1 more
- Volunteers
- 76 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia
Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)
This study is a Phase II, placebo-controlled, double-blind, randomized trial in 480 participants with atherosclerotic cardiovascular disease (ASCVD) or ASCVD-risk equivalents (for example, diabetes and familial…
- Conditions
- Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia, Diabetes
- Trial name
- ORION-1 (NCT02597127)
- Testing
- ALN-PCSSC, Normal Saline
- Where
- 54 sites in United States, Canada and 3 more
- Volunteers
- 501 people
- Sponsor
- The Medicines Company
Hepatic Encephalopathy
Deprescribing Proton Pump Inhibitors to Reduce Post-TIPS Hepatic Encephalopathy
A total of 40 patients taking proton pump inhibitors (PPIs) who undergo transjugular intrahepatic portosystemic shunt (TIPS) creation as part of routine clinical care will be randomized in 1:1 fashion to either continue or…
- Trial name
- NCT05070351
- Testing
- PPI deprescribing
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Duke University
Schizophrenia and Disorders With Psychotic Features
One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome
The purpose of this study is to explore the impact of ziprasidone on the distribution of metabolic syndrome risk factors in a population of patients presenting with glucose intolerance, dyslipidemia and/or elevated waist…
- Trial name
- NCT00748566
- Testing
- Ziprasidone HCL (oral)
- Where
- 32 sites in Canada
- Volunteers
- 172 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Obesity
Growth Hormone, Cardiovascular Risk, and Visceral Adiposity
This study will compare growth hormone levels and cardiovascular risk markers in normal weight and overweight women and men. In women and men with increased abdominal weight, growth hormone (GH) versus placebo will be…
- Trial name
- NCT00131378
- Testing
- Nutropin AQ growth hormone
- Where
- United States
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Diabetes Mellitus
Risk Identification of the GlucoTab System in Routine Use
Identification of risks of the GlucoTab system in routine use.
- Trial name
- NCT02053077
- Where
- Austria
- Volunteers
- 150 people
- Sponsor
- Medical University of Graz
PreDiabetes, Hyperglycemia
Effectiveness and Cost-Effectiveness of Fully-Automated Digital vs. Human Coach-Based Diabetes Prevention Programs
The purpose of this research study is to compare the effectiveness of a fully automated digital diabetes prevention program to standard of care human coach-based diabetes prevention programs for promoting clinically meaningful…
- Conditions
- PreDiabetes, Hyperglycemia, Glucose, High Blood, Overweight
- Trial name
- NCT05056376
- Testing
- Digital Diabetes Prevention Program (dDPP), Human Coach-based Diabetes Prevention Program (hDPP)
- Where
- 2 sites in United States
- Volunteers
- 368 people
- Sponsor
- Johns Hopkins University
Diabetes, Hypertension
Combined Behavioral and Pharmacological Intervention for Cardiovascular Risk Reduction in Diabetic Patients
The purpose of this research is to study whether a multidisciplinary education in Diabetes and intervention for cardiac risk reduction in a group setting to modify patient behavior and adjust medications can achieve diabetes…
- Conditions
- Diabetes, Hypertension, Dyslipidemia, Coronary Arteriosclerosis
- Trial name
- NCT00357955
- Testing
- Behavioral counseling and peer support, Interactive Education, Role modeling
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- Providence VA Medical Center
Obesity, Overweight
Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)
The purpose of this study is to determine the effects of NB relative to placebo on major adverse cardiovascular events (MACE) such as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in overweight and…
- Trial name
- NCT01601704
- Testing
- NB32, PBO, Weight Management Program
- Where
- 224 sites in United States
- Volunteers
- 8,910 people
- Sponsor
- Orexigen Therapeutics, Inc
Cardiovascular Diseases, Metabolic Syndrome X
Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome
The purpose of the study is to test higher versus lower doses of aspirin on markers of atherosclerosis in patients at risk of a first heart attack.
- Conditions
- Cardiovascular Diseases, Metabolic Syndrome X, Atherosclerosis
- Trial name
- PAD (NCT00272311)
- Testing
- Aspirin
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Florida Atlantic University
Cardiovascular Disease, Chronic Kidney Disease
Vascular Risk After Kidney Transplantation
Hypothesis: Nontraditional risk factors, such as inflammation, vitamin D deficiency, elevated PTH, insulin resistance, homocysteine, or uric acid, contribute to cardiovascular disease progression after kidney transplant.
- Conditions
- Cardiovascular Disease, Chronic Kidney Disease, Diabetes, Vitamin D Deficiency
- Trial name
- NCT00374595
- Where
- United States
- Volunteers
- 338 people
- Sponsor
- University of Nebraska
Lipid Metabolism Disorders
Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
This study is to demonstrate therapeutic comparability of Fluvastatin sodium Extended Release Tablets 80 mg QD and Fluvastatin sodium Immediate Release Capsules 40 mg BID in LDL-C lowering from baseline to week 12 (endpoint) in…
- Trial name
- NCT01551173
- Testing
- Fluvastatin sodium
- Where
- China
- Volunteers
- 436 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).
The aim of the present study is to investigate the safety of BI 10773 treatment in patients with Type 2 Diabetes Mellitus and high cardiovascular risk.
- Trial name
- NCT01131676
- Testing
- BI 10773 low dose, BI 10773 high dose
- Where
- 615 sites in United States, Argentina and 40 more
- Volunteers
- 7,064 people
- Sponsor
- Boehringer Ingelheim
Heart Diseases, Diabetes Mellitus, Type 2
Behavior Change Intervention for Cardiovascular Risk Reduction Among People Experiencing Homelessness
This single-arm trial of the Cardiovascular Risk Reduction Among People Experiencing Homelessness (CV-Homes) intervention alone (n=8) will test the perception and feasibility of anticipated study procedures.
- Conditions
- Heart Diseases, Diabetes Mellitus, Type 2, Pre-diabetes, Hypertension
- Trial name
- CV-Homes (NCT06025721)
- Testing
- Cardiovascular Risk Homeless Support
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Katherine Vickery
Age-Related Macular Degeneration, Genetic Testing
The Moran AMD Genetic Testing Assessment Study
The goals of this study are: To assess the impact of genetic testing for Age-related Macular Degeneration (AMD) on lifestyle behaviors as measured by systemic and ocular carotenoid status.
- Conditions
- Age-Related Macular Degeneration, Genetic Testing, Nutritional Biomarkers
- Trial name
- MAGENTA (NCT05265624)
- Testing
- Early disclosure of genetic testing results, Late disclosure of genetic testing results
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Paul S. Bernstein
Diabetes Mellitus, Type 2
Impact of Pharmacy Clinic on Diabetes Management
The Beaumont Hospital Royal Oak Outpatient Clinic (and other listed Beaumont recruiting locations) care for over 900 patients with diabetes.
- Trial name
- PharmaMD (NCT03377127)
- Testing
- Pharmacy Managed Diabetes Clinic (PMDC), Standard of Care (SOC)
- Where
- 4 sites in United States
- Volunteers
- 86 people
- Sponsor
- Corewell Health East
Hypercholesterolemia
Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo
The main purpose of this study is to evaluate the effect on mental state (known as "neurocognitive function") with use of Praluent.
- Trial name
- NCT02957682
- Testing
- Praluent (Alirocumab)
- Where
- 188 sites in United States, Bulgaria and 7 more
- Volunteers
- 2,176 people
- Sponsor
- Regeneron Pharmaceuticals
Diabetes
Risk Factors for Implant Bone Loss in Patients With Diabetes Mellitus
Dental implants are regarded as a standard of care in restoring missing teeth. Although there is a high prevalence of diabetics who receive dental implants, the relationship between dental implants and diabetes has not clearly…
- Trial name
- NCT00933491
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Hyperlipidemia, Hypertension
Medication Adherence Clinical Decision Support
More than 50% of adults treated for diabetes, hypertension, or lipid disorders have suboptimal medication adherence, a prominent barrier to continued improvement in chronic disease care in the United States.
- Conditions
- Hyperlipidemia, Hypertension, Diabetes, Medication Nonadherence
- Trial name
- ADH-Wizard (NCT03748420)
- Testing
- Adherence Intervention
- Where
- United States
- Volunteers
- 5,421 people
- Sponsor
- HealthPartners Institute